Summary
Edwards Lifesciences Corporation (EW) reported solid financial results for the second quarter and the first six months of 2024, demonstrating continued growth in its core structural heart disease business. Net sales increased by 7.0% year-over-year for the quarter and 7.9% for the first six months, primarily driven by strong performance in Transcatheter Aortic Valve Replacement (TAVR) and significant growth in Transcatheter Mitral and Tricuspid Therapies (TMTT). The company is strategically divesting its Critical Care product group, having entered into a definitive agreement for its sale in June 2024. This move is expected to sharpen focus on core growth areas and allow for reinvestment in interventional heart failure technologies. While the sale is pending regulatory approval, the financial results reflect Critical Care as discontinued operations. Despite some headwinds, including lower-than-expected TAVR growth in the US and currency fluctuations impacting gross margins, the company maintains a positive outlook, supported by ongoing investments in R&D and strategic acquisitions. Key financial highlights include continued revenue growth, robust operating income, and effective management of operating expenses. The company also provided updates on its ongoing tax litigations, which remain a significant contingency but are being actively managed. Overall, the report indicates a company strategically positioning itself for future growth while navigating competitive and regulatory landscapes.
Financial Highlights
50 data points| Revenue | $1.37B |
| Cost of Revenue | $275.50M |
| Gross Profit | $1.09B |
| R&D Expenses | $271.80M |
| SG&A Expenses | $447.50M |
| Operating Income | $366.50M |
| Net Income | $365.00M |
| EPS (Basic) | $0.61 |
| EPS (Diluted) | $0.61 |
| Shares Outstanding (Basic) | 602.10M |
| Shares Outstanding (Diluted) | 604.30M |
Key Highlights
- 1Net sales increased by 7.0% to $1.39 billion for the three months ended June 30, 2024, and by 7.9% to $2.73 billion for the six months ended June 30, 2024, driven by strong performance in TAVR and TMTT.
- 2The company announced a definitive agreement to sell its Critical Care product group for $4.2 billion, which is expected to close by the end of Q3 2024. The results of this segment are presented as discontinued operations.
- 3Transcatheter Mitral and Tricuspid Therapies (TMTT) sales saw significant growth of 74.7% for the quarter and 74.9% for the six months, largely due to the PASCAL system and the launch of the EVOQUE tricuspid valve replacement system.
- 4Operating income for the quarter increased by 36.7% to $369.1 million, and for the six months by 19.8% to $720.2 million, reflecting strong sales growth and management of expenses.
- 5The company repurchased 1.7 million shares for $150.0 million during the first six months of 2024, with $898.5 million remaining authorization for future share repurchases.
- 6R&D expenses increased in the period, reflecting continued investment in aortic transcatheter valve innovations and clinical trials.
- 7The company has substantial ongoing tax litigations, particularly concerning transfer pricing for Surgical/TAVR intercompany royalty transactions, with potential material impacts on financial statements.